Patents by Inventor Vernon C. Stevens

Vernon C. Stevens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8642330
    Abstract: Antibody compositions and methods for inhibition of the effects of gonadotropin hormones are provided. Methods for treating cancer and methods for regulating fertility are provided by administration of the antibody compositions to a mammalian subject in need thereof.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: February 4, 2014
    Assignee: Onconon, LLC
    Inventors: Edwin P. Rock, Vernon C. Stevens, Pierre L. Triozzi
  • Patent number: 7060284
    Abstract: Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: June 13, 2006
    Assignee: The Ohio State University
    Inventors: Pravin T. P. Kaumaya, Vernon C. Stevens, Pierre L. Triozzi
  • Patent number: 6783761
    Abstract: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: August 31, 2004
    Assignee: Aphton Corporation
    Inventors: Stephen Grimes, Dov Michaeli, Vernon C. Stevens
  • Patent number: 6716428
    Abstract: Endogenous protein hormones, fragments thereof including epitopes, and synthetic peptides mimicking epitope regions of hormones such as human chorionic gonadotropin can be conjugated to a foreign carrier or otherwise modified so as to produce antibodies in humans against the endogenous protein hormone. Synthetic analogs to the 38 to 57 sequence of the beta subunit of human chorionic gonadotropin have been found which upon conjugation to a suitable foreign carrier can be employed to raise a high level of antibodies to human chorionic gonadotropin with a significant decrease in antibodies reactive to human pituitary luteinizing hormones. Upon conjugation to a foreign carrier such analogs may be administered to humans to treat hormone-associated carcinomas and for purposes of contraception.
    Type: Grant
    Filed: October 6, 1999
    Date of Patent: April 6, 2004
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Publication number: 20020076416
    Abstract: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
    Type: Application
    Filed: May 4, 2001
    Publication date: June 20, 2002
    Inventors: Stephen Grimes, Dov Michaeli, Vernon C. Stevens
  • Patent number: 6217881
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 17, 2001
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 6146633
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 14, 2000
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 6143305
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 7, 2000
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 6096318
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 1, 2000
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 6039948
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 21, 2000
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 5891992
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 6, 1999
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 5817753
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: October 6, 1998
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 5698201
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 16, 1997
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 5006334
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: July 15, 1987
    Date of Patent: April 9, 1991
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 4855285
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: August 8, 1989
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 4767842
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: July 15, 1987
    Date of Patent: August 30, 1988
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 4762913
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: July 15, 1987
    Date of Patent: August 9, 1988
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 4713366
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: December 4, 1985
    Date of Patent: December 15, 1987
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 4691006
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: November 2, 1984
    Date of Patent: September 1, 1987
    Assignee: Ohio State University
    Inventor: Vernon C. Stevens
  • Patent number: 4526716
    Abstract: Modified hormones or fragments of hormones are useful in producing antibodies when administered to an animal. Said antibodies in turn cause neutralization of endogenous natural protein hormones. Also, non-endogenous proteins or peptides (for example viral proteins or fragments thereof) can be modified to increase an animal's immune response thereto. These modification may be accomplished by attaching various kinds of modifying groups to the hormone or fragment. Modification may, for example, be achieved by chemically coupling diazosulfanilic acid groups to the hormone or fragment. The protein hormones to which this procedure can be applied are mammalian protein reproductive hormones such as, for example, Follicle Stimulating Hormone (FSH), or Human Chorionic Gonadotropin (HCG). These modified polypeptides may be administered to animals for the purpose of contraception, abortion, or treatment of hormone-related disease states and disorders, including hormone-associated carcinomas.
    Type: Grant
    Filed: March 4, 1983
    Date of Patent: July 2, 1985
    Assignee: The Ohio State University
    Inventor: Vernon C. Stevens